...
首页> 外文期刊>Journal of ocular pharmacology and therapeutics: The official journal of the Association for Ocular Pharmacology and Therapeutics >The comparison of fluoroquinolones to nonfluoroquinolone antibacterial agents for the prevention of endophthalmitis in a rabbit model
【24h】

The comparison of fluoroquinolones to nonfluoroquinolone antibacterial agents for the prevention of endophthalmitis in a rabbit model

机译:氟喹诺酮类与非氟喹诺酮类抗菌剂在兔模型中预防眼内炎的比较

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Purpose: Topical antibacterial agents, used as an off-label indication, are frequently administered pre- and postoperatively to prevent endophthalmitis. We compared topical treatment with fluoroquinolone (FQ) anti-infectives to non-FQ antibacterial agents to prevent Staphylococcus aureus endophthalmitis. We hypothesize that FQ anti-infectives are more effective than non-FQ antibacterial agents for preventing endophthalmitis. Methods: Moxifloxacin 0.5%, ofloxacin 0.3%, gentamicin 0.3%, chloramphenicol 0.5%, polymyxin B/trimethoprim (10,000 units/mL/0.1%), povidone-iodine 5%, and saline were tested for topical treatment to prevent endophthalmitis. Topical treatment was applied every 15min for 1h (5 drops) to the left eye of 14 rabbits for each antibacterial agent and saline. After appropriate anesthesia, the anterior chambers were injected with 1×105 colony-forming units of a clinical endophthalmitis isolate of a S. aureus that was susceptible to all tested antibacterials. One drop was administered immediately and another 4 drops of topical treatment were applied over 24h after injection. At 24h postinjection, the eyes were graded for clinical signs of endophthalmitis (ocular discharge, conjunctivitis/scleral injection, limbal injection, hypopyon*, iritis*, anterior chamber cells*, anterior chamber flare*, corneal infiltration, and fibrin production*) using a severity scale (0-3). The indication of clinical endophthalmitis was a total score of 3.0 for the presentations marked with an asterisk. The data were analyzed using Fisher's Exact Randomization or Mann-Whitney nonparametric testing. Results: Topical ofloxacin (14/14, 100% without endophthalmitis) and moxifloxacin (13/14, 93%) prevented the clinical presentation of endophthalmitis significantly more frequently (P=0.03, Fisher's Exact Test (FE)) than topical gentamicin (7/14, 50%), povidone iodine (4/14, 29%), chloramphenicol (0/14, 0%), polymyxin B/trimethoprim (0/14, 0%), and saline (0/14, 0%). The median total clinical scores for the ofloxacin (0.5) and moxifloxacin (0.8) groups were significantly (P=0.008, Mann-Whitney Test (MW)) lower than gentamicin (5.7), chloramphenicol (17.5), polymyxin B/trimethoprim (21.2), povidone-iodine (15.5), and saline (18.7). Conclusions: The FQs, ofloxacin and moxifloxacin, were more effective in preventing endophthalmitis than the non-FQ antibacterial agents in a rabbit S. aureus endophthalmitis model. The observed results are consistent with the hypothesis that FQs penetrate into the anterior chamber at more effective levels than many of the common non-FQ antibacterial agents.
机译:目的:局部抗菌剂用作标签外适应症,通常在术前和术后给药以预防眼内炎。我们比较了用氟喹诺酮类(FQ)抗感染药和非FQ抗菌剂对局部治疗的效果,以预防金黄色葡萄球菌眼内炎。我们假设FQ抗感染药比非FQ抗菌药在预防眼内炎方面更有效。方法:对莫西沙星0.5%,氧氟沙星0.3%,庆大霉素0.3%,氯霉素0.5%,多粘菌素B /甲氧苄啶(10,000单位/mL/0.1%),聚维酮碘5%和生理盐水进行局部治疗以预防眼内炎。每15分钟对14只兔子的左眼进行局部治疗,持续1小时(5滴),每种抗生素和生理盐水都应使用。适当麻醉后,向前房注射1×105个对所有受试细菌敏感的金黄色葡萄球菌临床眼内炎分离株的菌落形成单位。立即注射一滴,在注射后24小时内再应用4滴局部治疗。注射后24小时,使用以下方法对眼睛进行眼内炎的临床体征分级(眼溢液,结膜炎/巩膜注射,角膜缘注射,垂体脓肿*,虹膜炎*,前房细胞*,前房耀斑*,角膜浸润和纤维蛋白生成*)严重性等级(0-3)。对于临床上眼内炎的适应症,其总评分> 3.0且带有星号。使用Fisher精确随机化或Mann-Whitney非参数检验对数据进行分析。结果:局部用氧氟沙星(14/14,无眼内炎的100%)和莫西沙星(13 / 14,93%)预防眼内炎的临床表现比局部用庆大霉素(7)显着更频繁(P = 0.03,Fisher精确检验(FE))。 / 14,50%),聚维酮碘(4/14,29%),氯霉素(0/14,0%),多粘菌素B /甲氧苄啶(0/14,0%)和盐水(0/14,0% )。氧氟沙星(0.5)和莫西沙星(0.8)组的中位总临床得分显着(P = 0.008,曼-惠特尼检验(MW))低于庆大霉素(5.7),氯霉素(17.5),多粘菌素B /甲氧苄啶(21.2) ),聚维酮碘(15.5)和盐水(18.7)。结论:在兔金黄色葡萄球菌性眼内炎模型中,氟喹沙星和莫西沙星的氟喹诺酮类药物比非氟喹诺酮类抗菌药物对预防眼内炎更有效。观察到的结果与FQ以比许多常见的非FQ抗菌剂更有效的水平渗透到前房的假设相一致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号